{"id":1195,"date":"2021-03-05T06:44:00","date_gmt":"2021-03-05T11:44:00","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=1195"},"modified":"2026-04-14T10:23:36","modified_gmt":"2026-04-14T14:23:36","slug":"neoventures-develops-aptamers-for-covid-19","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/fr\/neoventures-develops-aptamers-for-covid-19\/","title":{"rendered":"NeoVentures Develops Aptamers for COVID-19"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"1195\" class=\"elementor elementor-1195\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ea5a573 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ea5a573\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b9a2923\" data-id=\"b9a2923\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5cc9ec1 elementor-widget elementor-widget-text-editor\" data-id=\"5cc9ec1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>We have succeeded in developing high affinity and high specificity aptamers for both the spike protein (S1) and the nucleoprotein from SARS-CoV-2 (COVID-19). These aptamers have been characterized and are available for purchase. We are working with several partners globally to apply these aptamers in antigen based test systems using a wide variety of formats.<\/p><p>For our spike protein aptamers we started with recombinant S1 protein produced within HEK293 cells as these proteins are heavily glycosylated and this glycosylation has to be human relevant. We also performed counter selection against the S1 protein from SARS-CoV (SARS) in order to drive specificity for SARS-CoV-2. This was very successful as shown in the surface plasmon resonance imaging analysis below.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-65f4c42 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"65f4c42\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1c21c43\" data-id=\"1c21c43\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-68f5b62 elementor-widget elementor-widget-image\" data-id=\"68f5b62\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"504\" src=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment-768x504.png\" class=\"attachment-medium_large size-medium_large wp-image-1179\" alt=\"Aptamers for Covid-19\" srcset=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment-768x504.png 768w, https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment-300x197.png 300w, https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment-1024x672.png 1024w, https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment-1536x1008.png 1536w, https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment-2048x1344.png 2048w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-257448a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"257448a\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fb92896\" data-id=\"fb92896\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a385cef elementor-widget elementor-widget-text-editor\" data-id=\"a385cef\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Figure 1: SPRi binding curves , with our imbobilized Covid S1 aptamers after injection of S1 protein SARS-CoV( SARS) and S1 protein SARS CoV-2 ( Covid-19)<\/p><p>In applications, we have found that our aptamers for the nucleoprotein outperform those for spike protein by a margin that is larger than would be expected based on the higher abundance of nucleoprotein per virus particle. Coronavirus nucleoproteins function is to pack the RNA genome of the virus, so it is not surprising that they exhibit the capacity to bind to pretty much any single stranded oligonucleotide DNA or RNA. In our selection, we identified aptamers that outperformed all negative controls by orders of magnitude. Given the low levels of sensitivity needed for commercial relevance (1E3 to 1E5 VPs\/mL) the higher level of affinity of our oligonucleotides provides us with the necessary level of specificity required for detection.<\/p><p>If you are interested in discussing the use of our aptamers for COVID-19 please let us know by contacting us at <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"mailto:info@neoventures.ca\">info@neoventures.ca<\/a><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>We have succeeded in developing high affinity and high specificity aptamers for both the spike protein (S1) and the nucleoprotein from SARS-CoV-2 (COVID-19). These aptamers have been characterized and are available for purchase. We are working with several partners globally to apply these aptamers in antigen based test systems using a wide variety of formats.&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/fr\/neoventures-develops-aptamers-for-covid-19\/\" rel=\"bookmark\">Lire la suite &raquo;<span class=\"screen-reader-text\">NeoVentures Develops Aptamers for COVID-19<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":1179,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-1195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptamers for covid-19 | neoaptamers<\/title>\n<meta name=\"description\" content=\"NeoVentures has developed aptamers with high affinity and high specificity for spike protein (S1) and nucleoprotein for SARS-CoV-2 (COVID-19).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/fr\/neoventures-develops-aptamers-for-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamers for covid-19 | neoaptamers\" \/>\n<meta property=\"og:description\" content=\"NeoVentures has developed aptamers with high affinity and high specificity for spike protein (S1) and nucleoprotein for SARS-CoV-2 (COVID-19).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/fr\/neoventures-develops-aptamers-for-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T11:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T14:23:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2121\" \/>\n\t<meta property=\"og:image:height\" content=\"1392\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"partyinfrance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"partyinfrance\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/\"},\"author\":{\"name\":\"partyinfrance\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/34934951075d3d931c9216ed7f568fe6\"},\"headline\":\"NeoVentures Develops Aptamers for COVID-19\",\"datePublished\":\"2021-03-05T11:44:00+00:00\",\"dateModified\":\"2026-04-14T14:23:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/\"},\"wordCount\":288,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/annment.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/\",\"name\":\"Aptamers for covid-19 | neoaptamers\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/annment.png\",\"datePublished\":\"2021-03-05T11:44:00+00:00\",\"dateModified\":\"2026-04-14T14:23:36+00:00\",\"description\":\"NeoVentures has developed aptamers with high affinity and high specificity for spike protein (S1) and nucleoprotein for SARS-CoV-2 (COVID-19).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/annment.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/annment.png\",\"width\":2121,\"height\":1392,\"caption\":\"Aptamers for Covid-19\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/neoventures-develops-aptamers-for-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeoVentures Develops Aptamers for COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/34934951075d3d931c9216ed7f568fe6\",\"name\":\"partyinfrance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g\",\"caption\":\"partyinfrance\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptamers for covid-19 | neoaptamers","description":"NeoVentures has developed aptamers with high affinity and high specificity for spike protein (S1) and nucleoprotein for SARS-CoV-2 (COVID-19).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/fr\/neoventures-develops-aptamers-for-covid-19\/","og_locale":"fr_FR","og_type":"article","og_title":"Aptamers for covid-19 | neoaptamers","og_description":"NeoVentures has developed aptamers with high affinity and high specificity for spike protein (S1) and nucleoprotein for SARS-CoV-2 (COVID-19).","og_url":"https:\/\/neoaptamers.com\/fr\/neoventures-develops-aptamers-for-covid-19\/","og_site_name":"neoaptamers","article_published_time":"2021-03-05T11:44:00+00:00","article_modified_time":"2026-04-14T14:23:36+00:00","og_image":[{"width":2121,"height":1392,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment.png","type":"image\/png"}],"author":"partyinfrance","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"partyinfrance","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/"},"author":{"name":"partyinfrance","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/34934951075d3d931c9216ed7f568fe6"},"headline":"NeoVentures Develops Aptamers for COVID-19","datePublished":"2021-03-05T11:44:00+00:00","dateModified":"2026-04-14T14:23:36+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/"},"wordCount":288,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment.png","articleSection":["Uncategorized"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/","url":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/","name":"Aptamers for covid-19 | neoaptamers","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment.png","datePublished":"2021-03-05T11:44:00+00:00","dateModified":"2026-04-14T14:23:36+00:00","description":"NeoVentures has developed aptamers with high affinity and high specificity for spike protein (S1) and nucleoprotein for SARS-CoV-2 (COVID-19).","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2021\/03\/annment.png","width":2121,"height":1392,"caption":"Aptamers for Covid-19"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/neoventures-develops-aptamers-for-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"NeoVentures Develops Aptamers for COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/34934951075d3d931c9216ed7f568fe6","name":"partyinfrance","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/92a1a8baadc8edb75908400eb770e42f1cacc51799ca019260cdbb36ac3ab4f1?s=96&d=mm&r=g","caption":"partyinfrance"}}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/1195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/comments?post=1195"}],"version-history":[{"count":12,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/1195\/revisions"}],"predecessor-version":[{"id":6577,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/1195\/revisions\/6577"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media\/1179"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media?parent=1195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/categories?post=1195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/tags?post=1195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}